肿瘤

订阅

MedSci主页 / 所有栏目 / 肿瘤

多发性骨髓瘤治疗中遇上不良反应怎么办？

2022-03-21 梅斯医学 梅斯医学

多发性骨髓瘤
关注

多发性骨髓瘤是长期斗争的过程，谨遵医嘱，长期服药！

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1840645, encodeId=fd731840645a6, content=<a href='/topic/show?id=9401204912f' target=_blank style='color:#2F92EE;'>#不良反应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20491, encryptionId=9401204912f, topicName=不良反应)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e76f39, createdName=smartjoy, createdTime=Wed Oct 12 14:00:04 CST 2022, time=2022-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1890362, encodeId=f2f1189036251, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Wed Oct 05 15:00:04 CST 2022, time=2022-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1207174, encodeId=95d0120e17456, content=骨髓瘤全程管理，使更多患者获益, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7f812503221, createdName=Ara-C, createdTime=Wed Mar 30 11:11:55 CST 2022, time=2022-03-30, status=1, ipAttribution=)]
    2022-10-12 smartjoy

    #不良反应#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1840645, encodeId=fd731840645a6, content=<a href='/topic/show?id=9401204912f' target=_blank style='color:#2F92EE;'>#不良反应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20491, encryptionId=9401204912f, topicName=不良反应)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e76f39, createdName=smartjoy, createdTime=Wed Oct 12 14:00:04 CST 2022, time=2022-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1890362, encodeId=f2f1189036251, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Wed Oct 05 15:00:04 CST 2022, time=2022-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1207174, encodeId=95d0120e17456, content=骨髓瘤全程管理，使更多患者获益, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7f812503221, createdName=Ara-C, createdTime=Wed Mar 30 11:11:55 CST 2022, time=2022-03-30, status=1, ipAttribution=)]
    2022-10-05 jml2009

    #多发性#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1840645, encodeId=fd731840645a6, content=<a href='/topic/show?id=9401204912f' target=_blank style='color:#2F92EE;'>#不良反应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20491, encryptionId=9401204912f, topicName=不良反应)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e76f39, createdName=smartjoy, createdTime=Wed Oct 12 14:00:04 CST 2022, time=2022-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1890362, encodeId=f2f1189036251, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Wed Oct 05 15:00:04 CST 2022, time=2022-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1207174, encodeId=95d0120e17456, content=骨髓瘤全程管理，使更多患者获益, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7f812503221, createdName=Ara-C, createdTime=Wed Mar 30 11:11:55 CST 2022, time=2022-03-30, status=1, ipAttribution=)]
    2022-03-30 Ara-C

    骨髓瘤全程管理，使更多患者获益

    0

相关资讯

对症用药，无法移植治疗的多发性骨髓瘤患者怎么治？

新选择！

European Radiology：放射组学，让多发性骨髓瘤与转移瘤的鉴别不再头疼！

多发性骨髓瘤（MM）和转移瘤是两种最常见的椎体肿瘤，两者均可表现为软组织肿块或椎体破坏。由于发病年龄相似，其症状和影像学表现也有重叠，临床上可能出现误诊。然而，两种疾病的治疗方法却完全不同。

Lancet Oncol： 泊马度胺-地塞米松方案加用Isatuximab可显著延长复发/难治性多发性骨髓瘤患者的总生存期

泊马度胺-地塞米松方案加用Isatuximab可显著延长复发/难治性多发性骨髓瘤患者的总生存期。

Front Onco：基于 MRI 的骨髓放射组学诺模图预测多发性骨髓瘤患者的总生存期

基于 MRI 的骨髓放射组学可能是预测 MM总体生存期的另一个有用工具。

Blood：微小残留病灶阴性在多发性骨髓瘤中的预后意义

微小残留病灶阴性可预测多发性骨髓瘤患者的生存预后

复发不再害怕，多发性骨髓瘤有了治疗新选择！

多发性骨髓瘤治疗是长期斗争的过程，即使病情缓解，仍不能放松警惕！